CSIMarket
 
Prosomnus Inc   (NASDAQ: OSA)
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 17
 Employees -
 Revenues (TTM) (Millions $) 32
 Net Income (TTM) (Millions $) -30
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 1

Business Description


Prosomnus Inc is a medical technology company specializing in the design and production of oral devices for the treatment of sleep-related breathing disorders, particularly obstructive sleep apnea (OSA). The company's primary product is the Prosomnus Sleep Technologies, a custom-made oral appliance for OSA patients.

The Prosomnus Sleep Technologies aim to provide a comfortable and effective alternative to traditional continuous positive airway pressure (CPAP) therapy. These devices are designed to maintain an open and unobstructed airway by repositioning and stabilizing the jaw during sleep. They are custom-fit to each patient's unique dental anatomy, ensuring optimal comfort and treatment efficacy.

One of the key advantages of the Prosomnus Sleep Technologies is its compact and non-invasive nature. Unlike CPAP machines, which involve wearing a mask and relying on a constant airflow, the oral appliance is discreet and portable, allowing patients to sleep comfortably and freely move during the night. The devices can also be easily adjusted and fine-tuned to the patient's needs, promoting higher compliance and better treatment outcomes.

Additionally, Prosomnus Inc prioritizes research and innovation. They collaborate with leading sleep specialists and institutions to continually improve their products and contribute to the advancement of sleep-related breathing disorder treatments. The company's commitment to evidence-based practice and clinical outcomes ensures that their devices are safe, effective, and based on the latest scientific knowledge.

Overall, Prosomnus Inc offers a promising solution for individuals suffering from sleep-related breathing disorders. Their custom-made oral devices provide a comfortable and effective treatment option, improving patients' quality of sleep and overall well-being.


   Company Address: 5675 Gibraltar Drive Pleasanton 94588 CA
   Company Phone Number: 537-5337   Stock Exchange / Ticker: NASDAQ OSA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BSX        1.83% 
EW        1.48% 
MDT        1.24% 
PEN   -0.62%    
RMD   -0.03%    
SYK   -3.61%    
• View Complete Report
   



Clinical Study

Revolutionary Remote Patient Monitoring Device by ProSomnus Validates Promising Results for Effective Treatment of Obstructive Sleep Apnea

Published Thu, Feb 22 2024 1:30 PM UTC

In a groundbreaking development, ProSomnus, a leading innovator in the field of sleep medicine, has recently unveiled their next generation remote patient monitoring device for the management of Obstructive Sleep Apnea (OSA). The company s successful pilot study has demonstrated the device s efficacy and potential to revolutionize the treatment landscape for this prevalent s...

Product Service News

ProSomnus: Bridging the Gap to Ensure Uninterrupted Support for Obstructive Sleep Apnea Patients

Published Mon, Jan 29 2024 1:00 PM UTC

In a startling turn of events, Philips Respironics, a leading manufacturer of obstructive sleep apnea (OSA) devices, recently announced the recall and discontinuation of a significant number of its products due to health concerns. As the sleep apnea community reels from this unexpected setback, there is a pressing need for alternative solutions to ensure uninterrupted suppor...

Clinical Study

ProSomnus Precision Oral Appliance Devices Revolutionize Sleep Apnea Treatment, Showcasing Promising Clinical Results and Strong Patient Adherence

Published Tue, Dec 19 2023 1:00 PM UTC



In a recent press release, ProSomnus Inc announced groundbreaking data published by the Cureus Journal of Medical Science that demonstrates the successful treatment of obstructive sleep apnea (OSA) using their precision oral appliance devices. The findings suggest that patients using ProSomnus devices experienced a significant decrease in apnea-hypopnea index (AHI)...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.26
Working Capital Ratio 0.74
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.94 $
Revenues (TTM) 1.86 $
Cash Flow (TTM) -
Cash 0.3 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -
Receivable Turnover Ratio (TTM) 8.03
Inventory Turnover Ratio (TTM) 9.32
Asset Turnover Ratio (TTM) 1.39

Profitability Ratios Current
Gross Margin (MRQ) 53.06 %
Operating Margin (MRQ) -24.74 %
Net Margin (MRQ) -166.97 %
Net Cash Flow Margin (MRQ) 12.41 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.